Terms: = Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791 AND Prognosis
500 results:
1. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
[TBL] [Abstract] [Full Text] [Related]
2. Targeting Myeloid leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
3. [Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].
Osada Y; Kanai-Sudo H; Mizuki T; Tanosaki S; Suzuki K
Rinsho Ketsueki; 2024; 65(3):135-141. PubMed ID: 38569855
[TBL] [Abstract] [Full Text] [Related]
4. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
5. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
6. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract] [Full Text] [Related]
7. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
8. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
9. siRNA-mediated downregulation of BATF3 diminished proliferation and induced apoptosis through downregulating c-Myc expression in chronic myelogenous leukemia cells.
Dabbaghipour R; Khaze Shahgoli V; Safaei S; Amini M; Tabei S; Shanehbandi D; Rahbar Farzam O; Baradaran B; Entezam M
Mol Biol Rep; 2024 Jan; 51(1):100. PubMed ID: 38217769
[TBL] [Abstract] [Full Text] [Related]
10. Oncogenic lncRNA FAM215A promotes the malignant cell phenotypes of acute myeloid leukemia (AML) cell lines.
Li L; Xin L; Yang X; Zou Z
J Mol Histol; 2024 Feb; 55(1):97-108. PubMed ID: 38165572
[TBL] [Abstract] [Full Text] [Related]
11. [miR-181b-5p promotes cell proliferation and induces apoptosis in human acute myeloid leukemia by targeting PAX9].
Li B; Tao Q; Hu X; Li T; Bao Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Dec; 39(12):1074-1082. PubMed ID: 38140866
[TBL] [Abstract] [Full Text] [Related]
12. [Research Progress in Treatment of Chronic Lymphocytic leukemia --Review].
Zhang R; Xin R; Dou LP; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1910-1915. PubMed ID: 38071082
[TBL] [Abstract] [Full Text] [Related]
13. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid leukemia.
Lima K; Carvalho MFL; Pereira-Martins DA; Nogueira FL; de Miranda LBL; Nascimento MCD; Cavaglieri RC; Schuringa JJ; Machado-Neto JA; Rego EM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069220
[TBL] [Abstract] [Full Text] [Related]
14. Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
Kumar J; Ewalt MD; Zhang Y; Yao J; Thompson MC; Dogan A
Br J Haematol; 2024 Feb; 204(2):561-565. PubMed ID: 38031233
[TBL] [Abstract] [Full Text] [Related]
15. [Development of novel therapeutic agents for myelofibrosis].
Yamaguchi H
Rinsho Ketsueki; 2023; 64(10):1298-1305. PubMed ID: 37914245
[TBL] [Abstract] [Full Text] [Related]
16. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic leukemia.
Al-Sawaf O
Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
[TBL] [Abstract] [Full Text] [Related]
17. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
[TBL] [Abstract] [Full Text] [Related]
18. Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.
Jacob M; Wiedemann S; Brücher D; Pieper NM; Birkhold M; Särchen V; Jeroch J; Demes MC; Gretser S; Braun Y; Gradhand E; Rothweiler F; Michaelis M; Cinatl J; Vogler M
Br J Cancer; 2023 Nov; 129(10):1667-1678. PubMed ID: 37723317
[TBL] [Abstract] [Full Text] [Related]
19. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic leukemia.
Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
[TBL] [Abstract] [Full Text] [Related]
20. Dinaciclib synergizes with BH3 mimetics targeting bcl-2 and BCL-X
Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
[TBL] [Abstract] [Full Text] [Related]
[Next]
